WO2004049794A3 - Anticorps simple chaine - Google Patents

Anticorps simple chaine Download PDF

Info

Publication number
WO2004049794A3
WO2004049794A3 PCT/GB2003/005274 GB0305274W WO2004049794A3 WO 2004049794 A3 WO2004049794 A3 WO 2004049794A3 GB 0305274 W GB0305274 W GB 0305274W WO 2004049794 A3 WO2004049794 A3 WO 2004049794A3
Authority
WO
WIPO (PCT)
Prior art keywords
single chain
transgenic mouse
chain antibodies
antibodies produced
antibody
Prior art date
Application number
PCT/GB2003/005274
Other languages
English (en)
Other versions
WO2004049794A2 (fr
Inventor
Marianne Brueggemann
Original Assignee
Babraham Inst
Marianne Brueggemann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Babraham Inst, Marianne Brueggemann filed Critical Babraham Inst
Priority to AU2003295086A priority Critical patent/AU2003295086A1/en
Publication of WO2004049794A2 publication Critical patent/WO2004049794A2/fr
Publication of WO2004049794A3 publication Critical patent/WO2004049794A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Abstract

La présente invention concerne des anticorps simple chaîne. L'invention concerne également une souris transgénique et des anticorps simple chaîne produits par cette souris transgénique. Selon un mode de réalisation décrit dans cette invention, la souris transgénique peut exprimer un anticorps simple chaîne, tel qu'un anticorps à chaîne lourde uniquement; l'expression comprend, soit la sécrétion ou la diffusion extracellulaire, soit les deux.
PCT/GB2003/005274 2002-12-03 2003-12-03 Anticorps simple chaine WO2004049794A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003295086A AU2003295086A1 (en) 2002-12-03 2003-12-03 Single chain antibodies produced in a transgenic mouse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0228210.1 2002-12-03
GB0228210A GB0228210D0 (en) 2002-12-03 2002-12-03 Single chain antibodies

Publications (2)

Publication Number Publication Date
WO2004049794A2 WO2004049794A2 (fr) 2004-06-17
WO2004049794A3 true WO2004049794A3 (fr) 2004-12-02

Family

ID=9949000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/005274 WO2004049794A2 (fr) 2002-12-03 2003-12-03 Anticorps simple chaine

Country Status (3)

Country Link
AU (1) AU2003295086A1 (fr)
GB (1) GB0228210D0 (fr)
WO (1) WO2004049794A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981932B2 (en) 2021-06-16 2024-05-14 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
BRPI0513577A (pt) * 2004-07-22 2008-05-06 Univ Erasmus Medical Ct moléculas ligantes
GB0601511D0 (en) * 2006-01-25 2006-03-08 Univ Erasmus Medical Ct Binding Molecules 2
BRPI0706750A2 (pt) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct geração de anticorpos de cadeia pesada em animais transgênicos
GB0618345D0 (en) * 2006-09-18 2006-10-25 Univ Erasmus Binding molecules
WO2008074839A2 (fr) 2006-12-19 2008-06-26 Ablynx N.V. Séquences d'acides aminés dirigées contre les gpcr et polypeptides les contenant pour le traitement de maladies et de troubles liés au gpcr
CA2672965C (fr) 2006-12-19 2018-02-06 Ablynx N.V. Sequences d'acides amines dirigees contre une metalloproteinase de la famille adam et polypeptides les comprenant a des fins de traitement de maladies et troubles lies a adam
GB0706628D0 (en) * 2007-04-04 2007-05-16 Univ Erasmus Germ-line manipulation 1
PL2336329T3 (pl) 2007-06-01 2013-04-30 Omt Inc Kompozycje i sposoby hamowania endogennych genów immunoglobulin i wytwarzanie transgenicznych ludzkich idiotypowych przeciwciał
EP2215125A1 (fr) 2007-11-27 2010-08-11 Ablynx N.V. Procédé d'obtention de produits de construction de polypeptide comprenant au moins deux anticorps à domaine unique
CA2720013C (fr) 2008-04-03 2016-02-16 Bart De Strooper Anticorps a domaine unique capables de moduler une activite de la bace
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
WO2009124931A2 (fr) 2008-04-07 2009-10-15 Ablynx Nv Séquences d'acides aminés dirigées contre les voies notch et leurs utilisations
US9212226B2 (en) 2008-05-16 2015-12-15 Ablynx N.V. Amino acid sequences directed against CXCR4 and other GPCRs and compounds comprising the same
EP2288623B1 (fr) * 2008-05-23 2013-07-10 Ablexis, LLC Procédé de génération d anticorps à domaine vl unique dans des animaux transgéniques
EP3424526A1 (fr) 2008-06-05 2019-01-09 Ablynx NV Domaines variables uniques d'immunoglobuline contre la protéine g d'enveloppe du virus de la rage et leurs utilisation pour le traitement et la prévention de la rage
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
US9260508B2 (en) 2008-12-19 2016-02-16 Ablynx N.V. Method for generation of immunoglobulin sequences
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
DK2491056T3 (da) 2009-10-22 2021-10-25 Univ Twente Vhh til anvendelse i vævsreparation, organregenerering, organudskiftning og vævskonstruktion
KR101553244B1 (ko) 2009-12-10 2015-09-15 리제너론 파마슈티칼스 인코포레이티드 중쇄 항체를 만드는 마우스
WO2011073180A1 (fr) 2009-12-14 2011-06-23 Ablynx N.V. Anticorps à domaine variable unique dirigés contre ox4ql, produits de recombinaison et utilisation thérapeutique
WO2011083141A2 (fr) 2010-01-08 2011-07-14 Ablynx Nv Procédé de production de séquences d'immunoglobulines par utilisation de particules de lipoprotéines
ES2603559T5 (es) 2010-02-08 2021-02-22 Regeneron Pharma Cadena ligera común de ratón
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8937164B2 (en) 2010-03-26 2015-01-20 Ablynx N.V. Biological materials related to CXCR7
US9101674B2 (en) 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
US9556273B2 (en) 2010-03-29 2017-01-31 Vib Vzw Anti-macrophage mannose receptor single variable domains for targeting and in vivo imaging of tumor-associated macrophages
GB201014715D0 (en) 2010-09-06 2010-10-20 Vib Vzw Nanobodies stabilizing functional conformational states of GPCRS
MX2018014787A (es) * 2010-08-02 2023-02-14 Regeneron Pharma Ratones que producen proteinas de union que comprenden dominios vl.
EP2609119B1 (fr) 2010-08-26 2017-10-18 Agrosavfe N.V. Protéines de liaison d'antigènes polysaccharides chitineux
EP2638068B1 (fr) 2010-11-08 2018-12-26 Novartis AG Polypeptides se liant aux récepteurs de cxcr2
WO2012122512A1 (fr) 2011-03-10 2012-09-13 Hco Antibody, Inc. Production recombinante de mélanges d'anticorps monocaténaires
JP6181040B2 (ja) 2011-03-28 2017-08-16 アブリンクス エン．ヴェー． 二特異性抗ｃｘｃｒ７免疫グロブリン単一可変ドメイン
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
EP4282882A3 (fr) 2011-06-21 2024-03-06 Vib Vzw Domaines de liaison dirigés contre des complexes gpcr: protéine g et leurs utilisations
ES2872081T3 (es) 2011-08-05 2021-11-02 Regeneron Pharma Ratones con cadena ligera universal humanizada
WO2013059230A1 (fr) 2011-10-17 2013-04-25 Regeneron Pharmaceuticals, Inc. Souris à chaîne lourde d'immunoglobuline limitée
JP6327750B2 (ja) 2011-12-20 2018-05-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化軽鎖マウス
EP2617732A1 (fr) 2012-01-19 2013-07-24 Vib Vzw Outils et procédés pour l'expression de protéines de membrane
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
EP2855526B1 (fr) 2012-05-24 2018-11-07 VIB vzw Domaines variables individuels contre le récepteur mannose des macrophages pour le ciblage et l'imagerie in vivo de macrophages associés à des tumeurs
KR20240042174A (ko) 2012-06-12 2024-04-01 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
CA2899693C (fr) 2013-01-30 2023-03-14 Vib Vzw Nouveaux polypeptides chimeriques utilises pour cribler des composes et decouvrir des medicaments
ES2745772T3 (es) 2013-02-05 2020-03-03 Vib Vzw Agentes de unión al receptor muscarínico de la acetilcolina y usos de los mismos
SG11201505383UA (en) 2013-02-20 2015-08-28 Regeneron Pharma Non-human animals with modified immunoglobulin heavy chain sequences
US9617339B2 (en) 2013-03-15 2017-04-11 Vib Vzw Method of imaging a cardiovascular disease with an anti-macrophage mannose receptor immunoglobulin single variable domain
WO2014141192A1 (fr) 2013-03-15 2014-09-18 Erasmus University Medical Center Génération d'anticorps à chaînes lourdes uniquement
CA2936728C (fr) 2014-01-30 2023-06-20 Vib Vzw Agents de liaison aux recepteurs opioides et leurs utilisations
EP3119811B1 (fr) 2014-03-21 2019-10-30 Regeneron Pharmaceuticals, Inc. Protéines de liaison à l'antigène avec des caracteristiques de liaison distincts
JP6636498B2 (ja) 2014-03-21 2020-01-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 単一ドメイン結合タンパク質を作る非ヒト動物
JP2018508224A (ja) 2015-03-19 2018-03-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗原を結合する軽鎖可変領域を選択する非ヒト動物
WO2016187594A1 (fr) 2015-05-21 2016-11-24 Harpoon Therapeutics, Inc. Protéines trispécifiques de liaison et méthodes d'utilisation
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN109071627B (zh) 2016-02-05 2023-04-04 奥里尼斯生物科学私人有限公司 Cd8结合剂
JP2019507762A (ja) 2016-03-07 2019-03-22 ブイアイビー ブイゼットダブリュー Ｃｄ２０結合単一ドメイン抗体
CA3017813C (fr) 2016-03-17 2021-12-07 Oslo Universitetssykehus Hf Proteines de fusion ciblant des macrophages associes aux tumeurs pour le traitement du cancer
CN109563141A (zh) 2016-05-13 2019-04-02 奥里尼斯生物科学公司 对非细胞结构的治疗性靶向
WO2017201488A1 (fr) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Protéine de liaison à l'albumine sérique à domaine unique
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
US10544221B2 (en) 2016-05-20 2020-01-28 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
WO2018014260A1 (fr) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Protéines de liaison antigènes multi-spécifiques et leurs procédés d'utilisation
WO2018068201A1 (fr) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et ses variants contre ctla-4
WO2018098354A1 (fr) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Protéine de liaison à l'antigène membranaire spécifique de la prostate
EP3544629A4 (fr) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. Protéines trispécifiques ciblang le psma et procédés d'utilisation
US11384154B2 (en) 2017-02-06 2022-07-12 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
CN113896792A (zh) 2017-05-12 2022-01-07 哈普恩治疗公司 间皮素结合蛋白质
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
WO2018222587A1 (fr) 2017-05-30 2018-12-06 The Regents Of The University Of California Nanocorps contre le facteur d'inhibition (cif) du régulateur de la conductance transmembranaire de la fibrose kystique (cftr)
WO2019000223A1 (fr) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. Activateurs de cellules effectrices immunitaires d'anticorps chimériques et leurs procédés d'utilisation
MX2020003915A (es) 2017-10-13 2020-10-08 Harpoon Therapeutics Inc Proteinas trispecificas y metodos de uso.
MX2020003856A (es) 2017-10-13 2020-08-13 Harpoon Therapeutics Inc Proteinas de union a antigenos de maduracion de celulas b.
EP3732203A4 (fr) 2017-12-28 2021-12-15 Nanjing Legend Biotech Co., Ltd. Anticorps et leurs variants dirigés contre pd-l1
EP3732202A4 (fr) 2017-12-28 2022-06-15 Nanjing Legend Biotech Co., Ltd. Anticorps à domaine unique et leurs variants dirigés contre tigit
CA3084518A1 (fr) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Anticorps a domaine unique et des variants de celui-ci diriges contre pd-1
JP2021513361A (ja) 2018-02-05 2021-05-27 オリオニス バイオサイエンシーズ，インコーポレイテッド 線維芽細胞結合物質およびその使用
KR20200138720A (ko) 2018-03-30 2020-12-10 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
GB2576914A (en) 2018-09-06 2020-03-11 Kymab Ltd Antigen-binding molecules comprising unpaired variable domains produced in mammals
CA3114038A1 (fr) 2018-09-25 2020-04-02 Harpoon Therapeutics, Inc. Proteines de liaison a dll3 et methodes d'utilisation
KR20220008866A (ko) 2019-05-14 2022-01-21 하푼 테라퓨틱스, 인크. EpCAM 결합 단백질 및 사용 방법
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
EP4106806A1 (fr) 2020-02-21 2022-12-28 Harpoon Therapeutics, Inc. Protéines de liaison à flt3 et méthodes d'utilisation
CA3169910A1 (fr) 2020-02-28 2021-09-02 Shanghai Henlius Biotech, Inc. Constructions anti-cd137 et utilisations connexes
CA3169939A1 (fr) 2020-02-28 2021-09-02 Jie Xue Construction anti-cd137 et son utilisation
US20230235075A1 (en) 2020-06-02 2023-07-27 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
CA3190328A1 (fr) 2020-07-29 2022-02-03 Dynamicure Biotechnology Llc Constructions anti-cd93 et leurs utilisations
WO2022156908A1 (fr) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Procédé de préparation d'une composition lyophilisée
WO2022157373A1 (fr) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Compositions et kits pour l'imagerie in vivo de la sarcoïdose cardiaque
WO2022156907A1 (fr) 2021-01-25 2022-07-28 Vrije Universiteit Brussel Procédé et kit pour marquer une biomolécule avec un ou plusieurs marqueurs détectables, comprenant un marqueur radioactif
CA3209052A1 (fr) 2021-02-19 2022-08-25 Rafael Cristian CASELLAS Anticorps a domaine unique qui neutralisent le sars-cov-2
CN116917322A (zh) 2021-02-19 2023-10-20 沙裴隆有限公司 针对pd-l1及cd47的双特异性单域抗体及其用途
EP4296283A1 (fr) 2021-02-19 2023-12-27 SHAPERON Inc. Anticorps à domaine unique dirigé contre pd-l1 et son utilisation
JP2024512252A (ja) 2021-02-19 2024-03-19 シャペロン インク． Ｃｄ４７に対する単一ドメイン抗体及びその用途
EP4301472A1 (fr) 2021-03-05 2024-01-10 Dynamicure Biotechnology LLC Constructions anti-vista et leurs utilisations
EP4314049A1 (fr) 2021-03-25 2024-02-07 Dynamicure Biotechnology LLC Constructions anti-igfbp7 et leurs utilisations
EP4355785A1 (fr) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Constructions anti-cd3 et utilisations associées
WO2022269473A1 (fr) 2021-06-23 2022-12-29 Janssen Biotech, Inc. Matériaux et procédés pour régions charnières dans des récepteurs exogènes fonctionnels
WO2023057508A1 (fr) 2021-10-05 2023-04-13 Vrije Universiteit Brussel Domaines variables uniques d'immunoglobuline marqués par fluorescence
WO2024018426A1 (fr) 2022-07-22 2024-01-25 Janssen Biotech, Inc. Transfert amélioré d'instructions génétiques à des cellules immunitaires effectrices
WO2024054929A1 (fr) 2022-09-07 2024-03-14 Dynamicure Biotechnology Llc Constructions anti-vista et leurs utilisations
EP4349374A1 (fr) 2022-10-05 2024-04-10 Vrije Universiteit Brussel Domaines variables uniques d'immunoglobulines du récepteur de l'activateur du plasminogène anti-urokinase
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085944A2 (fr) * 2001-04-24 2002-10-31 Erasmus Universiteit Rotterdam Immunoglobuline 2
WO2003000737A2 (fr) * 2001-06-21 2003-01-03 The Babraham Institute Locus de la chaine legere $g(l) de souris

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085944A2 (fr) * 2001-04-24 2002-10-31 Erasmus Universiteit Rotterdam Immunoglobuline 2
WO2002085945A2 (fr) * 2001-04-24 2002-10-31 Erasmus Universiteit Rotterdam Immunoglobuline 1
WO2003000737A2 (fr) * 2001-06-21 2003-01-03 The Babraham Institute Locus de la chaine legere $g(l) de souris

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BRUEGGEMANN MARIANNE ET AL: "Strategies for expressing human antibody repertoires in transgenic mice", IMMUNOLOGY TODAY, vol. 17, no. 8, 1996, pages 391 - 397, XP004034600, ISSN: 0167-5699 *
KELLERMANN SIRID AIMÉE ET AL: "Antibody discovery: the use of transgenic mice to generate human monoclonal antibodies for therapeutics.", CURRENT OPINION IN BIOTECHNOLOGY. DEC 2002, vol. 13, no. 6, December 2002 (2002-12-01), pages 593 - 597, XP002293544, ISSN: 0958-1669 *
NGUYEN V K ET AL: "Camel heavy-chain antibodies: diverse germline V(H)H and specific mechanisms enlarge the antigen-binding repertoire.", THE EMBO JOURNAL. 1 MAR 2000, vol. 19, no. 5, 1 March 2000 (2000-03-01), pages 921 - 930, XP002188947, ISSN: 0261-4189 *
NGUYEN VIET KHONG ET AL: "Heavy-chain only antibodies derived from dromedary are secreted and displayed by mouse B cells.", IMMUNOLOGY. MAY 2003, vol. 109, no. 1, May 2003 (2003-05-01), pages 93 - 101, XP002293545, ISSN: 0019-2805 *
RIECHMANN L ET AL: "Single domain antibodies: comparison of camel VH and camelised human VH domains.", JOURNAL OF IMMUNOLOGICAL METHODS. 10 DEC 1999, vol. 231, no. 1-2, 10 December 1999 (1999-12-10), pages 25 - 38, XP004187632, ISSN: 0022-1759 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11981932B2 (en) 2021-06-16 2024-05-14 Janssen Biotech, Inc. Materials and methods for the manufacture of pluripotent stem cells

Also Published As

Publication number Publication date
AU2003295086A1 (en) 2004-06-23
GB0228210D0 (en) 2003-01-08
WO2004049794A2 (fr) 2004-06-17
AU2003295086A8 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2004049794A3 (fr) Anticorps simple chaine
WO2007133290A8 (fr) Anticorps anti-ox40l et méthodes correspondantes
WO2007136893A3 (fr) Anticorps anti fgf19 et leurs méthodes d'utilisation
EP2275448A3 (fr) Fragments d'anticorps monovalent et leur utilisation thérapeutique
WO2004099249A3 (fr) Variants fc optimises et leurs procedes de generation
WO2004029207A3 (fr) Variants fc optimises et methodes destinees a leur generation
WO2007130697A8 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2007060117A3 (fr) Proteines effectrices chimeres se liant a la keratine
WO2007008943A3 (fr) Proteines optimisees qui ciblent la molecule ep-cam
PT1546734E (pt) Anticorpos monoclonais de amiloide beta n 11 truncados, composições, métodos e utilizações
WO2005118857A3 (fr) Procedes et agents de balayage de composes capables de moduler l'expression de vegf
AU2003219277A1 (en) Intracellular antibodies
WO2008060705A8 (fr) Anticorps anti-dll4 et leurs procédés d'utilisation
WO2003087131A3 (fr) Variants d'anticorps anti-her2
WO2006125207A3 (fr) Compositions et procedes permettant d'accroitre la stabilite d'un anticorps
WO2006110651A3 (fr) Ecrans reflechissants et leurs procedes de fabrication
SG166090A1 (en) Il-13 binding agents
WO2002075274A3 (fr) Methode et trousse pour le suivi des maladies neurodegeneratives
WO2007127506A3 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2005074645A3 (fr) Procedes et compositions permettant de moduler l'angiogenese
WO2004046188A3 (fr) Anticorps anti-ras activee
WO2004046186A3 (fr) Intracorps
WO2004060295A3 (fr) Techniques permettant d'induire et de maintenir une tolerance immunitaire
WO2006098998A3 (fr) Procedes et compositions de modulation de l'integrite vasculaire
WO2008030564A3 (fr) Anticorps aglycosylés et procédés de fabrication et d'utilisation de ces anticorps

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP